Brixton Biosciences Secures $2M NIH Grant for Pain Relief Innovations

Brixton Biosciences, a company in the clinical-stage life sciences sector, has been granted initial funding totaling $2 million from the National Institutes of Health (NIH). This funding is part of the broader NIH Helping to End Addiction Long-term® Initiative, commonly known as the NIH HEAL Initiative®. The specific grant, numbered R44AR084998, aims to support the development of Neural Ice™, a pioneering injectable solution designed to offer prolonged pain relief without the use of drugs. This initiative is pivotal to the NIH's strategy to combat the opioid crisis by promoting scientific advancements that minimize the need for opioids in pain management.

Neural Ice™ represents a significant innovation in pain relief, providing a non-addictive, long-lasting option for individuals suffering from chronic and post-operative pain. The NIH HEAL Initiative is focused on addressing the widespread opioid public health crisis by funding research that seeks new methods to understand, manage, and treat pain, as well as to prevent opioid misuse and addiction. Neural Ice™ aligns with these goals as a novel, drug-free pain management solution.

Sameer Sabir, CEO and Co-Founder of Brixton Biosciences, emphasized the importance of this NIH award. He stated, "Our award from the NIH HEAL Initiative is a significant step forward in addressing the urgent need for non-opioid pain management solutions. This funding will further advance Neural Ice, helping us bring safer, non-addictive options to a broad array of patients who suffer from chronic and post-surgical pain. We're proud to contribute to the fight against opioid misuse and addiction. We truly believe Neural Ice will change the landscape of pain relief."

The NIH grant will facilitate the refinement of Neural Ice™ and hasten its clinical application. Initially focused on chronic knee pain, the development will now expand to other indications. By emphasizing non-pharmacological treatments, the initiative supports a wider healthcare mission aimed at reducing opioid dependence while enhancing patient outcomes.

The award from the NIH HEAL Initiative underscores Brixton Biosciences' commitment to addressing critical public health challenges. The collaboration advances Brixton's innovative pain management research, contributing to the larger effort to mitigate opioid misuse across the nation.

Brixton Biosciences emerged from Massachusetts General Brigham and is dedicated to developing new therapies for pain treatment. The company is led by a team of seasoned managers and prominent medical advisors, fostering a patient-focused approach backed by rigorous research. Historically, the field of pain management has been dominated by systemic medications, but Brixton Biosciences aims to address unmet needs with its innovative treatments. Neural Ice™, for instance, offers a drug-free, locally targeted, and long-lasting solution for pain relief, highlighting the company's commitment to providing effective and non-addictive alternatives.

In summary, the NIH HEAL Initiative's grant to Brixton Biosciences represents a significant stride toward advancing non-opioid pain management solutions. Neural Ice™ is poised to transform pain relief, offering a safer and more sustainable option for patients, and contributing to the broader effort to combat the opioid crisis.